Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
Michael L. Mohler, Arunima Sikdar, Suriyan Ponnusamy, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 2124-2124
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 165
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Weiguo Xiang, Lijie Zhao, Xin Han, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13487-13509
Open Access | Times Cited: 112
Targeting the Androgen Signaling Axis in Prostate Cancer
Charles Dai, Scott M. Dehm, Nima Sharifi
Journal of Clinical Oncology (2023) Vol. 41, Iss. 26, pp. 4267-4278
Open Access | Times Cited: 58
Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
Edris Choupani, Mohammad Mahmoudi Gomari, Saeed Zanganeh, et al.
Pharmacological Reviews (2022) Vol. 75, Iss. 2, pp. 309-327
Open Access | Times Cited: 39
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 23
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
Ritesh P. Bhole, Payal R. Kute, Rupesh V. Chikhale, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106720-106720
Closed Access | Times Cited: 23
PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
Yulu Zhang, Annan Ming, Junyan Wang, et al.
Pharmacological Research (2024) Vol. 205, pp. 107234-107234
Open Access | Times Cited: 8
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Jian Huang, Biyun Lin, Benyi Li
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 31
3D based generative PROTAC linker design with reinforcement learning
Baiqing Li, Ting Ran, Hongming Chen
Briefings in Bioinformatics (2023) Vol. 24, Iss. 5
Closed Access | Times Cited: 18
DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer
Shaoqiang Guo, Miaomiao Miao, Yufeng Wu, et al.
Oncogene (2024) Vol. 43, Iss. 19, pp. 1399-1410
Open Access | Times Cited: 7
A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives
Si Ha, Guoshun Luo, Hua Xiang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16128-16154
Closed Access | Times Cited: 24
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 494-494
Open Access | Times Cited: 5
Emerging Biomarker-Guided Therapies in Prostate Cancer
Jasna Deluce, Luisa M. Cardenas, Aly‐Khan A. Lalani, et al.
Current Oncology (2022) Vol. 29, Iss. 7, pp. 5054-5076
Open Access | Times Cited: 19
The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches
Nur Erysha Sabrina Jefferi, Asma’ ‘Afifah Shamhari, Nur Khayrin Zulaikha Noor Azhar, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 826-826
Open Access | Times Cited: 12
Targeted Degradation of Androgen Receptor by VNPP433-3β in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation
Elizabeth Thomas, Retheesh S. Thankan, Puranik Purushottamachar, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1198-1198
Open Access | Times Cited: 11
A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance
Andrea Alegre‐Martí, Alba Jiménez-Panizo, Adrián Martínez-Tébar, et al.
Science Advances (2023) Vol. 9, Iss. 11
Open Access | Times Cited: 11
Therapeutic targeting of the polyglutamine androgen receptor in Spinal and Bulbar Muscular Atrophy
Agamjot Sangotra, Andrew P. Lieberman
Expert Opinion on Therapeutic Targets (2025), pp. 1-13
Open Access
Investigation of absorption, metabolism, and excretion of [14C]pruxelutamide (GT0918), an androgen receptor antagonist in humans
Yuandong Zheng, Sheng Ma, Yali Yuan, et al.
British Journal of Clinical Pharmacology (2025)
Closed Access
Structure–Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer
Maoxu Xiao, Si Ha, Jiacheng Zhu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5567-5590
Closed Access | Times Cited: 3
Targeting androgen receptor for prostate cancer therapy: From small molecules to PROTACs
Ioannis Avgeris, Dimanthi Pliatsika, Sotiris S. Nikolaropoulos, et al.
Bioorganic Chemistry (2022) Vol. 128, pp. 106089-106089
Closed Access | Times Cited: 14
Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model
Retheesh S. Thankan, Elizabeth Thomas, Puranik Purushottamachar, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106700-106700
Open Access | Times Cited: 8
Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics
Wendy Effah, Marjana Khalil, Dong‐Jin Hwang, et al.
Steroids (2024) Vol. 210, pp. 109486-109486
Closed Access | Times Cited: 2
A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway
Nane C Kuznik, Valeria Solozobova, Irene Lee, et al.
iScience (2022) Vol. 25, Iss. 5, pp. 104175-104175
Open Access | Times Cited: 9
Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia
Teng Aik Ong, Marniza Saad, Jasmine Lim, et al.
BMC Urology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor
Giulia Apprato, Giulia D’Agostini, Paolo Rossetti, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1206-1206
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top